We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu

Bupropion for the Treatment of Methamphetamine Dependence - 1

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00069251
Recruitment Status : Completed
First Posted : September 24, 2003
Last Update Posted : January 12, 2017
Information provided by:
National Institute on Drug Abuse (NIDA)

September 18, 2003
September 24, 2003
January 12, 2017
July 2003
Not Provided
  • Severity addiction
  • Methamphetamine use
Same as current
Complete list of historical versions of study NCT00069251 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
Bupropion for the Treatment of Methamphetamine Dependence - 1
Bupropion for the Treatment of Methamphetamine Dependence
The purpose of this study is to assess the efficacy and safety of bupropion in reducing methamphetamine use in subjects with methamphetamine dependence
A double-blind, placebo-controlled, parallel-group design study in which 100 subjects will be randomly assigned to placebo or bupropion for 12 weeks with follow-up assessments 4 weeks following treatment. Adaptive randomization will be used to balance treatment groups based on gender.
Phase 2
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double
Primary Purpose: Treatment
Amphetamine-Related Disorders
Drug: Bupropion
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
June 2005
Not Provided

Inclusion Criteria:

  • Subject must have methamphetamine dependence as determined by the DSM-IV diagnosis
  • Subject must be willing to comply with study procedures.
  • Ability to verbalize understanding of consent form, provide written consent, and verbalize willingness to complete study procedures
  • Be able to comply with protocol requirements

Exclusion Criteria:

  • Please contact site for more information.
Sexes Eligible for Study: All
18 Years to 65 Years   (Adult)
Contact information is only displayed when the study is recruiting subjects
United States
Not Provided
Not Provided
Not Provided
Not Provided
National Institute on Drug Abuse (NIDA)
Not Provided
Principal Investigator: Richard Rawson, Ph.D. University of California, Los Angeles
National Institute on Drug Abuse (NIDA)
July 2008

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP